Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
about
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsConstrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetesThe kinetics of αIIbβ3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy.Targeting von Willebrand factor and platelet glycoprotein Ib receptor.Naringin administration inhibits platelet aggregation and release by reducing blood cholesterol levels and the cytosolic free calcium concentration in hyperlipidemic rabbits.A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting.New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesVorapaxar: targeting a novel antiplatelet pathway.Extracellular matrix proteins in hemostasis and thrombosisAntiplatelet effects of qishen yiqi dropping pill in platelets aggregation in hyperlipidemic rabbits.Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers.Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelorTargeting platelet thrombin receptor signaling to prevent thrombosis.Controversies and future perspectives of antiplatelet therapy in secondary stroke preventionClopidogrel in acute coronary syndrome: implications of recent study findings.A comparison of the metabolism of clopidogrel and prasugrel.Platelet physiology and antiplatelet agents.Ticagrelor: from discovery to Phase III clinical trial.Ticagrelor: a review of its use in the management of acute coronary syndromes.Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk.Tutorial in oral antithrombotic therapy: biology and dental implicationsAntiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents.Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.Novel therapy based on camelid nanobodies.Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors.Ticagrelor: a review of its use in adults with acute coronary syndromes.Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with CYP2C19*2 homozygotes.Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry.Head-to-Tail Cyclic Peptide Inhibitors of the Interaction between Human von Willebrand Factor and Collagen.Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study
P2860
Q26775125-BA43858F-08B5-4D68-98B7-77D9582B5832Q28081462-6DE7DB02-0475-4E87-A637-04953BCB17FBQ30498119-8A645EC0-1589-49DC-8E34-CB86D12B6DECQ33392975-B211BF8A-D8FC-4833-9902-6AA3974ECB65Q33962162-D1C39B28-5692-44DC-A5FB-0057DAE97548Q35491484-F2F1660F-0FF0-4856-BE93-C69706FDD2F5Q35752611-E8A4AA84-DF77-43B4-A7F0-4B30D569EE52Q35752810-0AD14F37-60D0-46AB-B4C7-984536B960B1Q35762807-9146ECEE-DA65-4026-82A7-6CD4BE8FE56FQ36210649-1489D75C-44E1-401A-8BAF-36626460FE21Q36723867-9E5F4B5B-295E-42D3-8853-620D58AF76DDQ36807413-8C678944-D32A-4D81-93B0-2358CE95949CQ37280316-7DAEA242-FB37-4C9A-A3F5-FE08AD76C01EQ37782412-5DF68BE7-3238-4B12-ADBD-8CCEA9AF639EQ37786639-1FB3474D-9624-41BD-8CF6-13F70E3238C1Q37788682-D6C17B0F-40AB-4D18-976B-FAA1BBC53AB1Q37807427-6CCCE246-EA60-4D2D-AAB4-43CF413F85BDQ37818206-9AC0F6EC-A5DE-4FA9-AE72-D7BBA01226FCQ37875063-C427B230-6046-4F4F-BAD7-FD980CFAC852Q37990848-FB6F9C62-D7F9-4F03-88EC-21743895414DQ38058760-E6316D44-82DF-419C-BE83-4942D8A1EC95Q38092567-683EF2C0-48E3-43A6-B541-C13A6C41C60DQ38101275-6B5BD913-5578-4028-8262-66DEBE45C220Q38151563-680228CE-74A8-4605-8B3C-92B5CDCD78C7Q38151739-D0D55984-B43F-43B4-95EF-6D46D689BA60Q38177048-A890574B-AD6E-4BB7-B49F-5C054E4CC14CQ38352069-3A5622DA-798D-4D5A-B1A5-6579E8D17247Q41060485-14CD91F1-6A6B-4BD9-97C5-FD6BCF065C42Q41895739-65632D09-9459-4E2B-97B6-C018645A4AFDQ47213003-A6E614F1-2405-4E25-9054-7A4A565F1263Q47615826-41C09948-2A4B-413B-AA5A-FE92BF9CD644Q54335457-30E03970-DEF5-48FC-946B-363787954572Q58071120-1FEF7D46-607F-4509-B31D-772A2259E9BE
P2860
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pharmacokinetic, pharmacodynam ...... s targeting vascular diseases.
@ast
Pharmacokinetic, pharmacodynam ...... s targeting vascular diseases.
@en
type
label
Pharmacokinetic, pharmacodynam ...... s targeting vascular diseases.
@ast
Pharmacokinetic, pharmacodynam ...... s targeting vascular diseases.
@en
prefLabel
Pharmacokinetic, pharmacodynam ...... s targeting vascular diseases.
@ast
Pharmacokinetic, pharmacodynam ...... s targeting vascular diseases.
@en
P2860
P1476
Pharmacokinetic, pharmacodynam ...... s targeting vascular diseases.
@en
P2093
Bernd Jilma
Julia Krumphuber
P2860
P304
P356
10.1111/J.1476-5381.2009.00555.X
P407
P577
2009-12-24T00:00:00Z